Community post

A new ESCMID Study Group that will deal with phage therapy has been created: the ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA).

ESGNTA aims to explore non-traditional antibacterials including phage and phage-related products for therapy, as well as increase and support the knowledge in phage lysin and other protein research, and understanding carriers and applications optimal for use in clinical settings (ex: gel, nanoparticles, etc.).

You can visit the website of ESGNTA to learn more about its mission, objectives, and bylaws. Any ESCMID member can join (you can become an ESCMID member here) — please spread the word!

Many thanks to the ESGNTA inauguration committee: Prof. Ran Nir-Paz, Prof. Tristan Ferry, Dr. Patrick Soentjens, Prof. Zuzanna Drulis-Kawa, and Prof. Joana Azeredo, whose hard work resulted in the ESGNTA being created and accepted into ESCMID!